Is Axillary Lymph Node Dissection Necessary After Sentinel Lymph Node Biopsy in Patients with Mastectomy and Pathological N1 Breast Cancer?

Annals of Surgical Oncology

Volumn 21, Issue 13, 2014, Pages 4109-4123

  Fu, Yun ^a,b   Chung, Debra ^a   Cao, Minh An ^a   Apple, Sophia ^a   Chang, Helena ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TECHNETIUM SULFUR COLLOID TC 99M; CO 068; ERBB2 PROTEIN, HUMAN; INDOLE DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE DISSECTION; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MASTECTOMY; MENSTRUATION; OBSERVATION; OVERALL SURVIVAL; PATHOLOGICAL N1 BREAST CANCER; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL PREDICTION; ADJUVANT THERAPY; AXILLA; BLOOD; BREAST NEOPLASMS; CANCER STAGING; COMPARATIVE STUDY; FEMALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; LYMPH NODE EXCISION; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENYLPROPIONATES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84911972813     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3814-3     Document Type: Article

References (21)

1. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–293.
2. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553.
3. Krag D, Harlow S, Julian T. Breast cancer and the NSABP-B32 sentinel node trial. Breast Cancer. 2004;11:221-224; discussion 264–226.
4. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–7720.
5. Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003;89:648–652.
6. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636.
7. Jörger M, Senn H-J, Thürlimann B. St. Gallen 2009 recommendation on the treatment of early breast cancer: consensus and controversy. MEMO. 2009;2(4):229–231.
8. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305: 569–575.
9. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer: Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2009;7:122–192.
10. Harris SR, Hugi MR, Olivotto IA, Levine M. Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ. 2001;164:191–199.
11. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–888.
12. Kell MR, Burke JP, Barry M, Morrow M. Outcome of axillary staging in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010;120:441–447.
13. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–2953.
14. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17 Suppl 3: 343–351.
15. Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–2808.
16. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–1151.
17. Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543–550.
18. Pal A, Provenzano E, Duffy SW, et al. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95:302–309.
19. Lambert LA, Ayers GD, Meric-Bernstam F. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2007;14:2422–2423.
20. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–2559.
21. Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92:1368–1377.